Compare stocks

Santhera Pharmaceuticals Holding AG is a Swiss pharmaceutical company focused on the development and commercialization of innovative treatments for rare and debilitating diseases. The company's key areas of expertise include neuromuscular and pulmonary disorders. Santhera's product pipeline features several investigational drugs targeting conditions such as Duchenne muscular dystrophy and cystic fibrosis. Headquartered in Pratteln, Switzerland, the company leverages its scientific expertise and industry partnerships to advance its therapeutic offerings. Santhera's strategic focus on niche markets allows it to address unmet medical needs, providing potential opportunities for growth within specialized segments of the healthcare industry.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.